Slide 1: Fiscal Third Quarter Ended September 30, 2022 Earnings Presentation
Fiscal Third Quarter Ended September 30, 2022 Earnings Presentation November 1, 2022
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hop
Slide 3: Key Messages
Key Messages • Robust order growth1 of 20%+ in the quarter; 23% year-to-date • Consolidated organic revenue growth of 9.0%; Medical +20.7% and Industrial +2.0% • Medical continues to exhibit strong growth and performance, led by Nuclear Medicine • Industrial underperformed in Q3 as a result of FX he
Slide 4: Market Performance Update
Market Performance Update End market trends materializing in order book and growth CY21 % Market YTD Order Segment and End Market Commentary and Trends of Total Growth1 Growth2 Medical | CY21 Revenue ~$228M 34% of Total • Strong domestic performance from national account marketing strategy Radiation
Slide 5: Fiscal Third Quarter Ended September 30, 2022 Summary
Fiscal Third Quarter Ended September 30, 2022 Summary Strong Medical performance, Industrial momentum building YTD order growth of 23% compared to same period in 20211 Adjusted Revenue Performance 3-months ended Sep. 30, 2022 vs. Sep. 30, 2021 $ millions +8.7% Adjusted EPS of $0.03 for third quarter
Slide 6: Mirion Fiscal Third Quarter Ended September 30, 2022
Mirion | Fiscal Third Quarter Ended September 30, 2022 Adjusted Revenue Adjusted EBITDA and Margin Adjusted Gross Profit Margin Adjusted EPS $ millions | % percentage $ millions | % percentage % percentage | basis points $ millions % 3Q21 vs. 3Q22 Public company costs impacting Organic +9.0% Adj. EB
Slide 7: Medical Fiscal Third Quarter Ended September 30, 2022
Medical | Fiscal Third Quarter Ended September 30, 2022 Adjusted Revenue Adjusted EBITDA and Margin MEDICAL SEGMENT $ millions | % percentage $ millions | % percentage Nuclear Medicine % 3Q21 vs. 3Q22 Radiotherapy Organic +20.7% Medical Imaging +19.3% Occupational Dosimetry Acquisition +4.4% FX -1.8
Slide 8: Industrial Fiscal Third Quarter Ended September 30, 2022
Industrial | Fiscal Third Quarter Ended September 30, 2022 Adjusted Revenue Adjusted EBITDA and Margin INDUSTRIAL SEGMENT $ millions | % percentage $ millions | % percentage Nuclear Power % 3Q21 vs. 3Q22 Labs & Research Organic +2.0% Defense & Diversified Industrial Acquisition +6.0% -11.0% FX -8.1%
Slide 9: Leverage, Liquidity and Adjusted Free Cash Flow
Leverage, Liquidity and Adjusted Free Cash Flow As of September 30, 2022 Leverage Liquidity and Adjusted Free Cash Flow • Cash on hand as of September 30, 2022 of $58M • Total liquidity available of $140M incl. undrawn revolver of $82M • Revolving facility includes springing first lien net leverage
Slide 10: Updated Guidance for the 12 Months Ending December 31, 2022
Updated Guidance for the 12 Months Ending December 31, 2022 Reaffirming organic growth guidance, revised adjusted EBITDA guidance Category1 November 1, 2022 July 29, 2022 What we are seeing and expectations Reported Adj. Revenue Growth 3.5% to 5.5% 2% to 4% • FX continues to be a headwind vs. prior
Slide 11: Mirion Third Quarter 2022 Key Takeaways
Mirion Third Quarter 2022 Key Takeaways Sustained, broad-based order growth and robust backlog supporting go- forward momentum Continued strength in Medical; underperformance in Industrial due to timing- related challenges and ongoing friction within the operating environment Execution on Q4 target
Slide 12: Appendix
Appendix &
Slide 13: Backlog Trend | Q3 CY20 to Q3 CY22
Backlog Trend | Q3 CY20 to Q3 CY22 $ millions Hanhikivi Backlog Excl Hanhikivi $766 $753 $738 $726 $79 $716 $0 $703 $67 $693 $69 $0 $79 $72 $637 $621 $726 $687 $686 $693 $669 $637 $631 Q3 CY20 Q4 CY20 Q1 CY21 Q2 CY21 Q3 CY21 Q4 CY21 Q1 CY22 Q2 CY22 Q3 CY22 Note: Backlog figures on an as reported bas
Slide 14: Nine Quarter Segment Reconciliation – Medical
Nine Quarter Segment Reconciliation Medical Combined Successor (non-GAAP) Predecessor ($ in millions) Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Revenue $ 68.7 $ 66.8 $ 60.1 $ 57.5 $ 52.0 $ 52.1 $ 51.5 $ 31.7 $ 20.4 Revenue reduction from purchase accounting — — — 3.1 3.
Slide 15: Nine Quarter Segment Reconciliation – Industrial
Nine Quarter Segment Reconciliation Industrial Combined Successor (non-GAAP) Predecessor ($ in millions) Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Revenue $ 92.2 $ 109.0 $ 103.1 $ 120.3 $ 92.3 $ 127.9 $ 114.7 $ 119.0 $ 94.2 Revenue reduction from purchase accounting — —
Slide 16: Nine Quarter Segment Reconciliation – Corporate & Other
Nine Quarter Segment Reconciliation Corporate & Other Combined Successor (non-GAAP) Predecessor ($ in millions) Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Revenue $ — $ — $ — $ — $ — $ — $ — $ — $ — Revenue reduction from purchase accounting — — — — — — — — — Adjusted Re
Slide 17: Nine Quarter Segment Reconciliation – Consolidated
Nine Quarter Segment Reconciliation Consolidated Combined Successor (non-GAAP) Predecessor ($ in millions) Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Revenue $ 160.9 $ 175.8 $ 163.2 $ 177.8 $ 144.3 $ 180.0 $ 166.2 $ 150.8 $ 114.6 Revenue reduction from purchase accountin
Slide 18: Non-GAAP Reconciliations
Non-GAAP Reconciliations Consolidated – Income (loss) from Operations, Adjusted Gross Profit & Adjusted EBITDA Three Months Ended Three Months Ended September 30, 2022 September 30, 2021 ($ in millions) (Successor) (Predecessor) Net income (loss) $ (50.4) $ (46.7) Interest expense, net 13.1 43.8 Inc
Slide 19: Non-GAAP Reconciliations: Adjusted Earnings per Share
Non-GAAP Reconciliations Reconciliation of Adjusted Earnings per Share Three Months Ended September 30, 2022 ($ in millions) (Successor) Net loss attributable to Mirion Technologies, Inc. (Successor) / Mirion Technologies (TopCo), Ltd. (Predecessor) stockholders $ (47.1) Loss attributable to noncont
Slide 20: Share Count Details
Share Count Details As of September 30, 20221 Outstanding Fully Diluted Share Description Securities (Illustrative)2,3,4 Notes Shares of Class A Common Stock – Public 181,352,086 181,352,086 Outstanding shares as of close of trading on the New York Stock Exchange (NYSE) September 30, 2022 Shares f
Slide 21: Footnotes to Share Count and Adjusted Metrics
Footnotes to Share Count and Adjusted Metrics Share Count Consists of 181,352,086 shares of Class A common stock and 8,040,540 shares of Class B common stock outstanding as of September 30, 2022. Excludes (1) 18,750,000 founder shares which are shares of Class A common stock subject to vesting in th
Slide 22: Mirion
m MIRION TECHNOLOGIES MIR LISTED NYSE